Biosenta's Tri-Filler(TM) Nanoparticles Achieve 100% Killing of Pathogens at Industry-Low Dose in Peer-Reviewed Studies
Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - June 11, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today announced that two independent, peer-reviewed studies conducted at the University of Calgary confirmed that its proprietary Tri-Filler™ core-shell calcium hydroxide-calcium carbonate (CSCC™) nanoparticles achieved complete (100 %) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.
"Transforming a readily available mineral into a durable, broad-spectrum antimicrobial opens new opportunities for safer surfaces in hospitals, transit systems and homes," said Dr. Mehdi Mohammadi Ashani, lead author of both papers.
Key laboratory findings
The research, conducted and independently validated by University of Calgary scientists, is detailed in two recent peer-reviewed publications in Colloids and Surfaces A and The Canadian Journal of Chemical Engineering.¹ ²
These studies confirmed Tri-Filler's™ potent efficacy against multiple World Health Organization priority bacterial pathogens, including:
Gram-negative bacteria: Escherichia coli (E. coli), Pseudomonas aeruginosa
Gram-positive bacteria: Staphylococcus aureus (including MRSA)
These findings were validated using both Minimum Inhibitory Concentration (MIC) and Minimum Biocidal Concentration (MBC) protocols, with consistent 100% elimination rates at the 2.5 mg/mL threshold across these bacterial strains. Traditional biocides rely on frequent re-application and can trigger resistance or toxicity. The 100 % kill rates reported above were obtained under controlled laboratory conditions.
In addition, Biosenta has obtained similar promising results against other significant microbes, including the Gram-positive bacterium Enterococcus faecalis and fungi Candida auris and Candida albicans. These results are currently under preparation for peer-reviewed publication.
"Achieving 100 per cent eradication across three WHO-priority species by a more environmentally friendly biocide at such relatively low dose moves Tri-Filler™ into a class of its own and is a decisive step toward safer, longer-lasting antimicrobial surfaces," added Dr. Maen Husein, professor of chemical and petroleum engineering and senior author of the papers.
From personal loss to public good
Biosenta's president and CEO Am Gill lost his uncle to a hospital-acquired infection. That tragedy drives the company's mission and underpins a $140-thousand donation to the Alberta Centre for Advanced Diagnostics to accelerate nanoparticle research.
"We're turning grief into action," Gill said. "Embedding Tri-Filler™ into concrete, paint and coatings will let us stop pathogens at the surface and save lives."What happens next
Regulatory filings - Health Canada and U.S. EPA submissions for Tri-Filler™-enabled products are in preparation.
Manufacturing scale-up - Bench output already tops 170 kg day; full commercial plant design is under way.
About Biosenta Inc.
Biosenta Inc. develops innovative antimicrobial products that offer environmentally friendly solutions to a global market. Based in Toronto, Ontario and Calgary, Alberta, the company is dedicated to the advancement of technology that combats microbial growth in various materials. Biosenta's flagship product, Tri-Filler®, represents a breakthrough in antimicrobial technology, providing durable protection against a wide spectrum of bacteria, molds, and fungi.
For further inquiries, please contact:
Am Gill, President and CEO, Biosenta Inc.Email: info@biosenta.comPhone: 416-410-2019
For more information, visit our website: www.biosenta.com
References
N. Darwish, M. M. Ashani, A. Mehairi, I. A. Lewis, M. M. Husein, "Synthesis of uniform core-shell calcium hydroxide-calcium carbonate biocidal particles via encapsulation into dry ice," Canadian Journal of Chemical Engineering, 2025, 1. DOI: 10.1002/cjce.25670.
N. Darwish, M. M. Ashani, I. A. Lewis, M. M. Husein, "Controlled carbonation of Ca(OH)₂ surface and its application as an antibacterial particle," Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2024, 682. DOI: 10.1016/j.colsurfa.2023.132852.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable securities laws ("forward-looking statements"), including forward-looking statements relating the completion of the Transaction. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. If any such risks actually occur, they could impact the potential for discussion, agreement or completion of the Transaction and/or materially adversely affect the Company's business, financial condition or results of operations. In that case, the trading price of the Company's common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Disclaimer
The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255262
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Researchers find programme that could improve IVF outcomes
Around one in five women of childbearing age are living with obesity, defined by the World Health Organization as having a body mass index (BMI) over 30 kg/m². Compared with women in the healthy BMI range (18.5–24.9 kg/m²), those living with obesity are three times more likely to experience fertility problems and nearly twice as likely to have a miscarriage. Many turn to in vitro fertilisation (IVF) in the hope of having a baby. Women with obesity who are planning a pregnancy are already advised that losing weight can improve their chances of conceiving. Our research suggests that structured weight loss support may also improve outcomes for those seeking IVF. Our study analysed data from 12 international trials involving 1,921 women living with obesity, all planning IVF. It compared those offered a weight loss programme before IVF with those receiving standard care, which typically does not include such support. Women who took part in a weight loss programme had a 21% higher chance of becoming pregnant overall – whether naturally or through IVF. The biggest difference was in natural conceptions: the likelihood of getting pregnant without IVF rose by 47%, meaning some women avoided fertility treatment altogether. However, despite these higher pregnancy rates and no increase in miscarriage risk, there was no clear evidence of an effect on live birth rates. This may be because many of the included studies didn't track live birth outcomes – even though this is the result that matters most to patients. IVF access paradox In the UK, publicly funded IVF is restricted to women with a BMI under 30. Similar weight-based eligibility rules exist in many other countries. These policies disproportionately affect women from more deprived backgrounds and some ethnic groups, who are more likely to be living with obesity. The paradox is clear: women with obesity are more likely to need IVF, but less likely to be eligible for it. Some can afford private weight loss programmes to meet the BMI requirement. Others resort to unproven or unsafe methods to lose weight quickly, risking their health in order to access fertility care. Our research findings suggest that offering structured weight loss programmes to women with obesity who are otherwise ineligible for IVF could help more women become pregnant – and in some cases avoid IVF altogether. This approach could also make fertility treatment more equitable. Since the cost of weight loss support is relatively low compared with IVF, including it in the treatment pathway might offer better value for healthcare providers. Weight loss options before IVF The most effective non-surgical option for significant weight loss is a class of medications called GLP-1 receptor agonists – such as Wegovy or Mounjaro – which have been shown to lead to substantial weight reduction. However, these drugs should not be used during pregnancy, while trying to conceive, or while breastfeeding, as there's little safety data in humans – and animal studies suggest potential harm to foetal development. Anyone who becomes pregnant while taking GLP-1 drugs should stop immediately and consult a healthcare professional. For women planning to conceive soon, there are other safe and effective options, including structured support groups and low-energy diet programmes. The problem is that such services are not offered as part of standard IVF care. While some NHS weight management programmes exist, access is limited, waiting lists can be long, and most are aimed at people with obesity-related health conditions rather than those seeking fertility treatment. In many other countries, insurance coverage for weight loss support is similarly patchy, meaning these services must often be funded privately – a cost that can put them out of reach for those who could benefit most. The message from this research is clear: targeted, supportive weight loss programmes before IVF don't just improve pregnancy chances – they could also reduce the need for IVF, promote fairer access to fertility treatment, and save healthcare resources. The challenge now is making sure they're available to everyone who needs them, not just those who can afford to pay. Nerys M. Astbury is an Associate Professor in Health Behaviours at the University of Oxford. Moscho Michalopoulou is a Behavioural Scientist in the Nuffield Department of Primary Care Health Sciences at the University of Oxford. Pedro Melo is an NIHR Academic Clinical Lecturer in Obstetrics & Gynaecology in the Nuffield Department of Women's and Reproductive Health at the University of Oxford. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Axios
2 hours ago
- Axios
These states have the highest COVID cases right now as "stratus" variant erupts
Twelve states are seeing higher positivity rates for COVID-19 tests compared to the rest of the country, according to new data from the Centers for Disease Control and Prevention. Why it matters: Positivity rates are popping off as the "stratus" COVID variant surges throughout the country Driving the news: The CDC updated its regional data for COVID-19 test positivity on Monday, Aug. 11. The data accounts for the week ending on Aug. 2. Zoom in: The states with the highest COVID test positivity include: New Mexico (12%) Texas (12%) Oklahoma (12%) Arkansas (12%) Louisiana (12%) Nevada (11.3%) Arizona (11.3%) California (11.3%) Alaska (11.1%) Washington (11.1%) Oregon (11.1%) Idaho (11.1%) Worth noting: The rest of the country's test positivity rate ranks between 5% to 9.9%. The big picture: Overall, the CDC reports that the COVID-19 epidemic trend is "growing," with 45 states experiencing an increase in cases. No state has seen a decline in cases as of Aug. 5, per the CDC. Last Friday, the CDC upgraded the national wastewater viral activity for COVID-19 from "low" to "moderate," signaling a rise in cases nationwide. Higher wastewater activity was spotted in the Southeast, with Louisiana having a "very high" amount — the most nationwide. "Stratus" COVID-19 variant rises Context: The rise in COVID-19 cases amid an uptick in cases of the XFG "stratus" variant. Though it was first detected in January, the variant now accounts for 14% of cases in the U.S., and is the third-highest among all variants stateside, according to the CDC. The World Health Organization said XFG might be more likely to evade immune defenses. However, current COVID-19 vaccines "are expected to remain effective to this variant against symptomatic and severe disease," the WHO said in its June report. How to detect "stratus" COVID symptoms
Business Wire
3 hours ago
- Business Wire
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.
